

# Hui-li Wong

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9001753/publications.pdf>

Version: 2024-02-01

65  
papers

3,811  
citations

471371

17  
h-index

168321

53  
g-index

65  
all docs

65  
docs citations

65  
times ranked

7589  
citing authors

#	ARTICLE	IF	CITATIONS
1	Impact of the evolution in RAS mutation analysis in Australian patients with metastatic colorectal cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2022, , .	0.7	0
2	Diagnostic performance of positron emission tomography in the staging of pseudomyxoma peritonei. <i>European Journal of Surgical Oncology</i> , 2022, , .	0.5	0
3	Real-world staging computed tomography scanning technique and important reporting discrepancies in pancreatic ductal adenocarcinoma. <i>ANZ Journal of Surgery</i> , 2022, 92, 1789-1796.	0.3	2
4	Real-World Treatment and Outcomes of Metastatic Colorectal Cancer Patients With a Poor or Very Poor Performance Status. <i>Clinical Colorectal Cancer</i> , 2021, 20, e21-e34.	1.0	4
5	Subtype-Discordant Pancreatic Ductal Adenocarcinoma Tumors Show Intermediate Clinical and Molecular Characteristics. <i>Clinical Cancer Research</i> , 2021, 27, 150-157.	3.2	24
6	Circulating tumor DNA dynamics and recurrence risk in patients undergoing curative intent resection of colorectal cancer liver metastases: A prospective cohort study. <i>PLoS Medicine</i> , 2021, 18, e1003620.	3.9	88
7	Complete metabolic response following anaplastic lymphoma kinase (<sc>ALK</sc>) targeted therapy in a patient with adenocarcinoma of unknown primary with immunohistochemistry/fluorescence <sc>i>in situ</sc> hybridisation discordant <sc>ALK</sc> test results. <i>Internal Medicine Journal</i> . 2021. 51. 1355-1356.	0.5	0
8	Tumor infiltrating neutrophils and gland formation predict overall survival and molecular subgroups in pancreatic ductal adenocarcinoma. <i>Cancer Medicine</i> , 2021, 10, 1155-1165.	1.3	9
9	Characteristics and outcomes of participants in colorectal cancer biomarker trials versus a real-world cohort. <i>Acta Oncologica</i> , 2021, 60, 482-490.	0.8	1
10	Demonstrating the feasibility of collecting secondary, de-identified data on Australian patients receiving treatment as part of a Medicine Access Programme. <i>Internal Medicine Journal</i> , 2020, 50, 99-104.	0.5	2
11	Altered Gene Expression along the Glycolysis-Cholesterol Synthesis Axis Is Associated with Outcome in Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 135-146.	3.2	121
12	Simulating Progression-Free and Overall Survival for First-Line Doublet Chemotherapy With or Without Bevacizumab in Metastatic Colorectal Cancer Patients Based on Real-World Registry Data. <i>Pharmacoeconomics</i> , 2020, 38, 1263-1275.	1.7	3
13	CD8 <sup>+</sup> tumor-infiltrating lymphocytes within the primary tumor of patients with synchronous <i>de novo</i> metastatic colorectal carcinoma do not track with survival. <i>Clinical and Translational Immunology</i> , 2020, 9, e1155.	1.7	8
14	Circulating Tumour DNA to Guide Treatment of Gastrointestinal Malignancies. <i>Visceral Medicine</i> , 2020, 36, 388-396.	0.5	4
15	Endogenous Retrovirus Transcript Levels Are Associated with Immunogenic Signatures in Multiple Metastatic Cancer Types. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 1889-1897.	1.9	10
16	Real world outcomes in KRAS G12C mutation positive non-small cell lung cancer. <i>Lung Cancer</i> , 2020, 146, 310-317.	0.9	46
17	Health Economic Models for Metastatic Colorectal Cancer: A Methodological Review. <i>Pharmacoeconomics</i> , 2020, 38, 683-713.	1.7	10
18	Clinicopathological features of pancreatic cancer-related diabetes.. <i>Journal of Clinical Oncology</i> , 2020, 38, 675-675.	0.8	1

#	ARTICLE	IF	CITATIONS
19	Real-world outcomes for neoadjuvant capecitabine versus infusional 5-fluorouracil in the treatment of locally advanced rectal cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, e16124-e16124.	0.8	0
20	Immunohistochemical evaluation of the prognostic and predictive power of epidermal growth factor receptor ligand levels in patients with metastatic colorectal cancer. <i>Growth Factors</i> , 2020, 38, 127-136.	0.5	0
21	<i>NRG1</i> Gene Fusions Are Recurrent, Clinically Actionable Gene Rearrangements in <i>KRAS</i> Wild-Type Pancreatic Ductal Adenocarcinoma. <i>Clinical Cancer Research</i> , 2019, 25, 4674-4681.	3.2	121
22	Base excision repair deficiency signatures implicate germline and somatic <i>MUTYH</i> aberrations in pancreatic ductal adenocarcinoma and breast cancer oncogenesis. <i>Journal of Physical Education and Sports Management</i> , 2019, 5, a003681.	0.5	33
23	Outcomes and Characteristics of Patients Receiving Second-line Therapy for Advanced Pancreatic Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2019, 42, 196-201.	0.6	12
24	Chemotherapy and biologic use in the routine management of metastatic colorectal cancer in Australia: is clinical practice following the evidence?. <i>Internal Medicine Journal</i> , 2019, 49, 446-454.	0.5	12
25	A Novel Multiplex Droplet Digital PCR Assay to Identify and Quantify KRAS Mutations in Clinical Specimens. <i>Journal of Molecular Diagnostics</i> , 2019, 21, 214-227.	1.2	32
26	A pooled analysis of multicenter cohort studies of post-surgery circulating tumor DNA (ctDNA) in early stage colorectal cancer (CRC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 3518-3518.	0.8	5
27	Comprehensive genomic analysis of metastatic pancreatic ductal adenocarcinoma (mPDAC) reveals a significant proportion of clinical actionable aberrations.. <i>Journal of Clinical Oncology</i> , 2019, 37, e15753-e15753.	0.8	1
28	Left- versus right-side metastatic colorectal cancer: Teasing out clinicopathologic drivers of disparity in survival.. <i>Journal of Clinical Oncology</i> , 2019, 37, 623-623.	0.8	1
29	Comprehensive genomic analysis of metastatic pancreatic ductal adenocarcinoma (mPDAC) reveals a significant proportion of clinical actionable aberrations.. <i>Journal of Clinical Oncology</i> , 2019, 37, 273-273.	0.8	0
30	Molecular characterization of <i>ERBB2</i>-amplified colorectal cancer identifies potential mechanisms of resistance to targeted therapies: a report of two instructive cases. <i>Journal of Physical Education and Sports Management</i> , 2018, 4, a002535.	0.5	16
31	Detection and localization of surgically resectable cancers with a multi-analyte blood test. <i>Science</i> , 2018, 359, 926-930.	6.0	1,872
32	Molecular characterization of metastatic pancreatic neuroendocrine tumors (PNETs) using whole-genome and transcriptome sequencing. <i>Journal of Physical Education and Sports Management</i> , 2018, 4, a002329.	0.5	30
33	Stage-based Variation in the Effect of Primary Tumor Side on All Stages of Colorectal Cancer Recurrence and Survival. <i>Clinical Colorectal Cancer</i> , 2018, 17, e569-e577.	1.0	23
34	Previous Bevacizumab and Efficacy of Later Anti-“Epidermal Growth Factor Receptor Antibodies in Metastatic Colorectal Cancer: Results From a Large International Registry. <i>Clinical Colorectal Cancer</i> , 2018, 17, e593-e599.	1.0	6
35	Survival Impact of Adjuvant Chemotherapy for Resected Locally Advanced Rectal Adenocarcinoma. <i>Clinical Colorectal Cancer</i> , 2017, 16, e45-e54.	1.0	9
36	The impact of bevacizumab in metastatic colorectal cancer with an intact primary tumor: Results from a large prospective cohort study. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2017, 13, 314-321.	0.7	7

#	ARTICLE	IF	CITATIONS
37	Treatment sequencing and outcomes in synchronous metastatic rectal cancer.. Journal of Clinical Oncology, 2017, 35, 750-750.	0.8	1
38	Determinants of first-line treatment selection in advanced pancreatic ductal adenocarcinoma (PDAC).. Journal of Clinical Oncology, 2017, 35, 468-468.	0.8	1
39	Analysis of local chronic inflammatory cell infiltrate combined with systemic inflammation improves prognostication in stage II colon cancer independent of standard clinicopathologic criteria. International Journal of Cancer, 2016, 138, 671-678.	2.3	56
40	Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. Science Translational Medicine, 2016, 8, 346ra92.	5.8	1,036
41	Impact of Primary Tumor Site on Bevacizumab Efficacy in Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2016, 15, e9-e15.	1.0	45
42	Primary Tumor Resection and Overall Survival in Patients With Metastatic Colorectal Cancer Treated With Palliative Intent. Clinical Colorectal Cancer, 2016, 15, e125-e132.	1.0	8
43	Impact of Diabetes Status and Medication on Presentation, Treatment, and Outcome of Stage II Colon Cancer Patients. Journal of Cancer Epidemiology, 2015, 2015, 1-8.	0.5	13
44	Primary Tumor Resection in Patients With Metastatic Colorectal Cancer Is Associated With Reversal of Systemic Inflammation and Improved Survival. Clinical Colorectal Cancer, 2015, 14, 185-191.	1.0	42
45	Risk-Adjusted Pathologic Margin Positivity Rate: A Problematic Quality Indicator. Journal of Clinical Oncology, 2015, 33, 1410-1411.	0.8	4
46	Docetaxel in very elderly men with metastatic castration-resistant prostate cancer. Prostate International, 2015, 3, 42-46.	1.2	18
47	Problematic Use of Multiple Subgroup Analyses in Assessing the Impact of Aspirin in Prostate Cancer. Journal of Clinical Oncology, 2015, 33, 2226-2226.	0.8	1
48	Patterns of care and outcomes for elderly patients with metastatic colorectal cancer in Australia. Journal of Geriatric Oncology, 2015, 6, 387-394.	0.5	20
49	Circulating tumor DNA (ctDNA) as a marker of recurrence risk in stage II colon cancer (CC).. Journal of Clinical Oncology, 2014, 32, 11015-11015.	0.8	10
50	Safety and efficacy of bevacizumab and systemic therapy in metastatic colorectal cancer (mCRC) patients with peritoneal disease in the Treatment of Recurrent and Advanced Colorectal Cancer (TRACC) database.. Journal of Clinical Oncology, 2014, 32, 569-569.	0.8	1
51	Tumor burden (TB) as a prognostic indicator in patients with metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2014, 32, 572-572.	0.8	5
52	Are the survival benefits associated with primary resection in de novo metastatic colorectal cancer (mCRC) mediated by reversal of systemic inflammation?. Journal of Clinical Oncology, 2014, 32, 464-464.	0.8	0
53	Regular aspirin (ASA) use and survival in patients with PIK3CA-mutated metastatic colorectal cancer (CRC).. Journal of Clinical Oncology, 2014, 32, 386-386.	0.8	1
54	Massively parallel sequencing (MPS) of circulating DNA in patients with metastatic colorectal cancer (mCRC): Prognostic significance and early changes during chemotherapy (CT).. Journal of Clinical Oncology, 2013, 31, 11015-11015.	0.8	1

#	ARTICLE	IF	CITATIONS
55	Patterns of care of elderly patients with metastatic colorectal cancer.. Journal of Clinical Oncology, 2013, 31, e14640-e14640.	0.8	1
56	Can systemic inflammation at diagnosis predict benefit from primary resection in metastatic colorectal cancer (mCRC)?. Journal of Clinical Oncology, 2013, 31, 410-410.	0.8	1
57	Impact of diabetes on clinicopathologic and genetic features of colorectal cancer formation.. Journal of Clinical Oncology, 2013, 31, 426-426.	0.8	28
58	Metastatic colorectal cancer and management in public versus private hospitals: Similarities and differences.. Journal of Clinical Oncology, 2013, 31, 497-497.	0.8	1
59	Metastatic colorectal cancer (mCRC) with primary in situ: An Australian registry.. Journal of Clinical Oncology, 2013, 31, 498-498.	0.8	1
60	Is there a role for chemotherapy in metastatic colorectal cancer patients with a poor performance status?. Journal of Clinical Oncology, 2013, 31, 534-534.	0.8	0
61	Aspirin use and survival outcomes in patients (pts) with PIK3CA mutant colorectal cancer (CRC).. Journal of Clinical Oncology, 2013, 31, 3598-3598.	0.8	0
62	Understanding why some people with stage III colon cancer do not receive adjuvant chemotherapy.. Journal of Clinical Oncology, 2013, 31, e14608-e14608.	0.8	0
63	Primary tumor resection in metastatic colorectal cancer (mCRC): A prospective cohort study.. Journal of Clinical Oncology, 2013, 31, 3584-3584.	0.8	0
64	Is there a role for chemotherapy in metastatic colorectal cancer patients with a poor performance status?. Journal of Clinical Oncology, 2013, 31, e14583-e14583.	0.8	0
65	Vandetanib for the treatment of non-small-cell lung cancer. Expert Opinion on Pharmacotherapy, 2011, 12, 2271-2278.	0.9	3